-
公开(公告)号：EP2636666A4
公开(公告)日：2015-09-23
申请号：EP11838046
申请日：2011-11-01
IPC分类号： C07C219/20 , A61K31/16 , A61K31/165 , A61K31/231 , A61K31/255 , A61K31/40 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07C217/08 , C07C233/09 , C07C233/38 , C07C327/30
CPC分类号： C07C327/30 , A61K31/231 , C07C57/02 , C07C69/533 , C07C217/08 , C07C219/08 , C07C219/20 , C07C233/09 , C07C233/38 , C07C323/12 , C07C327/22 , C07C2601/08 , C07C2601/14 , C07D295/13
摘要： An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is -O-, -NR- or -S-, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury or an alleviating agent for side effect induced by administration of anti-cancer agents.
摘要翻译： 本发明的目的是提供一种新的反式-2-癸烯酸衍生物或其药学上可接受的盐，并提供含有所述化合物作为活性成分并且具有高度安全的神经营养因子样活性的药剂，或 减轻通过给予抗癌剂引起的副作用的作用。 作为本发明化合物的反式-2-癸烯酸衍生物或其药学上可接受的盐，具体由式（1）表示：（式中，Y为-O-，-NR-或-S- R为氢原子，烷基，二烷基氨基烷基等，W为二烷基氨基烷基等取代基），作为痴呆，阿尔茨海默氏病，帕金森病等预防或治疗剂等药剂具有相当高的用途， 抑郁症等，用于脊髓损伤的治疗或修复剂或通过施用抗癌剂诱导的副作用的减轻剂。
-
2.发明公开PROPHYLACTIC OR THERAPEUTIC DRUG FOR PERIPHERAL NEUROPATHY CAUSED BY ANTICANCER AGENT 审中-公开对于由抗癌剂预防和治疗剂引起的周围神经病
公开(公告)号：EP2671578A4
公开(公告)日：2014-04-02
申请号：EP12742127
申请日：2012-01-30
发明人： IINUMA MUNEKAZU , FURUKAWA SHOEI , NAIKI MITSURU , OKADA TOMOYUKI , MATSUMOTO TOMONORI , SAWADA KAZUYOSHI
IPC分类号： A61K31/23 , A61K31/231 , A61K45/06 , A61P25/02
CPC分类号： C07C69/533 , A61K9/0019 , A61K9/0095 , A61K9/10 , A61K31/23 , A61K31/231 , A61K45/06 , A61K47/6951 , B82Y5/00
-
公开(公告)号：EP2842942A4
公开(公告)日：2015-12-16
申请号：EP13781244
申请日：2013-04-26
IPC分类号： C07D207/16 , A61K9/70 , A61K31/40 , A61K31/401 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/5375 , A61K31/54 , A61K31/55 , A61K31/551 , A61K47/40 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/16 , A61P25/22
CPC分类号： C07D295/185 , C07D207/08 , C07D207/16 , C07D211/16 , C07D211/18 , C07D211/26 , C07D211/30 , C07D211/44 , C07D211/46 , C07D211/48 , C07D211/58 , C07D211/62 , C07D211/74 , C07D213/74 , C07D239/42 , C07D243/08 , C07D277/04 , C07D295/18
-
公开(公告)号：EP2842553A4
公开(公告)日：2015-12-09
申请号：EP13782289
申请日：2013-04-26
IPC分类号： A61K31/16 , A61K9/08 , A61K9/20 , A61K9/70 , A61K31/231 , A61K31/265 , A61K47/40 , A61P19/02 , A61P29/00
CPC分类号： A61K31/40 , A61K9/0019 , A61K9/0053 , A61K31/16 , A61K31/165 , A61K31/231 , A61K31/265 , A61K47/40 , A61K47/48969 , A61K47/6951
-
公开(公告)号：EP2695613A4
公开(公告)日：2014-03-26
申请号：EP12742101
申请日：2012-01-30
发明人： IINUMA MUNEKAZU , FURUKAWA SHOEI , NAIKI MITSURU , OKADA TOMOYUKI , MATSUMOTO TOMONORI , SAWADA KAZUYOSHI
IPC分类号： A61K31/231 , A61K31/201 , A61K31/23 , A61P29/00
CPC分类号： A61K31/23 , A61K31/231
-
6.发明公开
公开(公告)号：EP1537866A4
公开(公告)日：2009-03-11
申请号：EP03795352
申请日：2003-09-10
发明人： NAIKI MITSURU , NUMAZAWA TAKUMI
CPC分类号： A61K31/22
摘要： A drug for kidney failure containing, as the active ingredient, an oxaluric acid derivative which has an excellent effect of inhibiting the progress of kidney failure. The above-described compound, i.e., the oxaluric acid derivative has an excellent effect of inhibiting the progress of kidney failure by significantly inhibiting an increase in blood creatinine accompanying the progress of kidney failure while showing a high safety with little side effects. Thus, it is highly useful as a drug for kidney failure which is required to be administered over a long time.
-
7.发明公开
公开(公告)号：EP3120848A4
公开(公告)日：2017-03-08
申请号：EP15764236
申请日：2015-03-19
发明人： NAIKI MITSURU , NUMAZAWA TAKUMI , FUJISAWA HIROKI
IPC分类号： A61K31/37 , A61P11/00 , A61P19/02 , A61P29/00 , C07D311/18 , C07D405/12 , C07D409/12
CPC分类号： A61K31/37 , A61K9/007 , A61K31/381 , A61K31/4433 , A61K31/635 , C07D311/12 , C07D311/18 , C07D405/12 , C07D409/12
摘要： An object of the present invention is to provide a preventive or therapeutic agent for inflammatory diseases or degenerative intervertebral disk diseases. A coumarin derivative or a pharmaceutically acceptable salt or hydrate thereof which is an active ingredient of the preventive or therapeutic agent of the present invention exhibits an excellent suppressive action in a pharmacological test where production of inflammation-related factor such as inflammatory cytokine or fibrosis-related factor as an index. Moreover, said compound also exhibits an excellent suppressive action to pulmonary fibrosis model animals and degenerative intervertebral disk disease model animals. Accordingly, the present invention is very useful as a preventive or therapeutic agent for inflammatory diseases and degenerative intervertebral disk diseases.
-
8.发明公开
公开(公告)号：EP2075341A4
公开(公告)日：2010-09-08
申请号：EP07806736
申请日：2007-09-05
发明人： NAIKI MITSURU , OKADA TOMOYUKI
IPC分类号： C12Q1/68 , A61K31/715 , C12N15/12 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/158 , G01N33/50
-
公开(公告)号：EP2899187A4
公开(公告)日：2016-06-29
申请号：EP13838182
申请日：2013-09-20
发明人： NAIKI MITSURU , OKADA TOMOYUKI , SAWADA KAZUYOSHI , OGINO TAKASHI
IPC分类号： C07D311/18 , A61K31/352 , A61K31/381 , A61K31/4406 , A61P19/02 , A61P29/00 , C07D405/12 , C07D409/12
CPC分类号： C07D311/12 , A61K31/352 , C07D311/18 , C07D405/12 , C07D409/12
-
10.发明公开DNA CONTROLLING miR-140 EXPRESSION, AND SCREENING METHOD OF DRUGS USING SAID DNA 审中-公开用DNA控制MIR-140表达和使用该DNA的药物筛选方法
公开(公告)号：EP2835424A4
公开(公告)日：2015-09-23
申请号：EP13772453
申请日：2013-04-02
发明人： ASAHARA HIROSHI , YAMASHITA SATOSHI , NAIKI MITSURU , ABE KENTARO
IPC分类号： C12N15/113 , A01K67/027 , A61K45/00 , A61P19/00 , A61P19/02 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50
CPC分类号： G01N33/5308 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , C12N15/113 , C12N2310/141 , G01N2400/10 , G01N2500/02 , G01N2500/04 , G01N2500/10
摘要： An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.013 秒)
